Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs MiniMed Group Inc. Common Stock (MMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs MiniMed Group Inc. Common Stock — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $74.06M), while MiniMed Group Inc. Common Stock trades at $19.57 (market cap $5.38B). The key difference: MiniMed Group Inc. Common Stock is far larger — about 72.6× KraneShares Electric Vehicles and Future Mobility's market cap, and MiniMed Group Inc. Common Stock is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and MiniMed Group Inc. Common Stock for 0 Days on average.
| KARS | MMED | |
|---|---|---|
Market Cap | $74.06M | $5.38B |
Volume | 2,546 | 9,619,294 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $23.84 |
52-Week Low | $27.25 | $10.80 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $5.18B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →
